Ampicillin‑Sulbactam Lock Therapy for Hemodialysis Catheter‑Related Bloodstream Infections
Indications for Antibiotic Lock Therapy
Lock Solution Preparation and Administration
Contraindications and Pathogen‑Specific Considerations
Systemic Antimicrobial Therapy Requirements
Monitoring, Follow‑Up, and Duration of Therapy
Pharmacologic Rationale and Safety Considerations
Antibiotic Lock Therapy for Hemodialysis Catheters
Indications for Antibiotic Lock Therapy
- Prophylactic antimicrobial lock solution should be used in hemodialysis patients with long-term catheters who have a history of multiple catheter-related bloodstream infections (CRBSI) despite optimal adherence to aseptic technique, as recommended by the Infectious Diseases Society of America 7, 8, 9
- Antibiotic lock therapy is indicated for patients with CRBSI involving long-term catheters with no signs of exit site or tunnel infection for whom catheter salvage is the goal, according to the Clinical Infectious Diseases guidelines 10, 11
- Antibiotic lock should be used in patients with a history of multiple CRBSI despite optimal adherence to aseptic technique, as suggested by the Clinical Infectious Diseases guidelines 7, 8
Recommended Antibiotic Lock Protocol
- Antibiotic lock should not be used alone for active CRBSI; it should be used in conjunction with systemic antimicrobial therapy, with both regimens administered for 10-14 days, as recommended by the Clinical Infectious Diseases guidelines 10, 11
- For hemodialysis patients, the antibiotic lock solution should be renewed after every dialysis session, according to the Clinical Infectious Diseases guidelines 10, 11
- The antibiotic is combined with heparin and instilled into each catheter lumen at the end of each dialysis session, as suggested by the Clinical Infectious Diseases guidelines 11, 12
- For vancomycin locks, the concentration should be at least 1000 times higher than the MIC (e.g., 5 mg/mL) of the microorganism involved, as recommended by the Clinical Infectious Diseases guidelines 10, 11
Effectiveness Based on Pathogen
- Success rates for antibiotic lock therapy vary by pathogen, with 87%-100% for gram-negative pathogens, 75%-84% for Staphylococcus epidermidis, and only 40%-55% for hemodialysis-associated CRBSI due to S. aureus, according to the Clinical Infectious Diseases guidelines 11, 12
- Catheter removal is recommended for CRBSI due to S. aureus and Candida species, instead of treatment with antibiotic lock and catheter retention, unless there are unusual extenuating circumstances, as suggested by the Clinical Infectious Diseases guidelines 10, 11
Important Considerations and Caveats
- Antibiotic concentrations must be 100 to 1000 times greater to kill sessile bacteria within a biofilm than to kill planktonic bacteria, as noted by the Clinical Infectious Diseases guidelines 13
- Recurrent bacteremia after parenteral therapy is more likely to occur if therapy is administered through a retained catheter than if the catheter is removed, according to the Clinical Infectious Diseases guidelines 10
- At this time, there are insufficient data to recommend an ethanol lock for the treatment of CRBSI, as stated by the Clinical Infectious Diseases guidelines 10, 11
- Surveillance blood cultures should be obtained 1 week after completion of an antibiotic course for CRBSI if the catheter has been retained, as recommended by the Clinical Infectious Diseases guidelines 14
Ampicillin‑Sulbactam Lock Therapy for Catheter‑Related Bloodstream Infections
Indications & Patient Selection
- Antibiotic lock therapy is indicated for patients with a confirmed catheter‑related bloodstream infection caused by ampicillin‑susceptible Enterococcus species. [15][16][17][18]
Antibiotic Solution Preparation
Target Concentrations
- The lock solution should contain ampicillin at 10 mg/mL (equivalent to ampicillin‑sulbactam 15 mg/mL in the 2:1 fixed combination); this concentration remains physically stable and does not precipitate. [15][16][17][18]
Heparin Compatibility
- Two heparin concentrations are validated as compatible with the 10 mg/mL ampicillin solution: 10 IU/mL (low) and 5,000 IU/mL (high). Both maintain solution stability for at least 14 days. [15][16][17][18]
Preparation Steps
| Step | Action | Details |
|---|---|---|
| 1 | Reconstitute ampicillin‑sulbactam | Use sterile water to obtain a stock of ~250 mg ampicillin / 125 mg sulbactam per mL (≈250 mg/mL ampicillin). |
| 2 | Dilute to lock concentration | Mix 1 mL of the stock solution with 24 mL of 0.9 % NaCl to achieve 10 mg/mL ampicillin. [15] |
| 3 | Add heparin (choose one) | • For 10 IU/mL final: add 0.01 mL of heparin 1,000 IU/mL per mL of antibiotic solution. • For 5,000 IU/mL final: add 1 mL of heparin 5,000 IU/mL per mL of antibiotic solution. [15][16][17][18] |
| 4 | Mix | Gently agitate the solution for ~10 seconds to ensure homogeneity. [16][17] |
Administration Protocol
- After each dialysis session, instill 2–5 mL of the prepared ampicillin‑sulbactam/heparin lock into each catheter lumen (volume sufficient to fill the lumen without systemic exposure).
- Clamp the catheter immediately and allow the lock to dwell until the next dialysis session (typically 48–72 hours for thrice‑weekly dialysis).
- Renew the lock solution after every dialysis session for the entire treatment course. [16][17]18
Mandatory Concurrent Systemic Antibiotics
- Lock therapy must be combined with systemic antimicrobial therapy for 10–14 days.
- Empiric systemic regimen for hemodialysis patients:
- Vancomycin 20 mg/kg loading dose administered during the last hour of dialysis, followed by 500 mg during the last 30 minutes of subsequent sessions.
- Gram‑negative coverage with either ceftazidime 1 g or cefazolin 20 mg/kg administered after each dialysis session. [16][17]18
- Once susceptibilities confirm ampicillin‑susceptible Enterococcus, targeted systemic therapy with ampicillin‑sulbactam (dose adjusted for dialysis) may be used.
Expected Outcomes
- Enterococcus infections that are ampicillin‑susceptible respond well to ampicillin‑sulbactam lock therapy. [15][16][17][18]
All facts are derived from peer‑reviewed studies published in *Clinical Infectious Diseases* (2009) and are supported by the cited references.